Alar Pharmaceuticals

6785.TWO

8.43 USD

-0.43

-4.85%

Overview

Last close

8.43 usd

Market cap

562.80M usd

52 week high

9.84 usd

52 week low

3.40 usd

Target price

9.17 usd

Valuation

P/E

N/A

Forward P/E

N/A

Price/Sales

14181.006

Price/Book Value

7.3397

Enterprise Value

488.26M usd

EV/Revenue

12317.4421

EV/EBITDA

413.1064

Key financials

Revenue TTM

39639.35 usd

Gross Profit TTM

28566.91 usd

EBITDA TTM

-4.06M usd

Earnings per Share

-0.01 usd

Dividend

0.01 usd

Total assets

78.46M usd

Net debt

-20.81M usd

About

Alar Pharmaceuticals Inc., a drug development company, focuses on developing long-acting release drug products for CNS disorders and chronic diseases in Taiwan. The company develops ALA-1000 for the treatment of opioid use disorder. Its pre-clinical stage product includes ALA-1300 and ALA-2000 for the treatment of opioid use disorder; ALA-4000 to treat Parkinson's disease; ALA-3000 for treating treatment-resistant depression; and ALA-5000 to treat schizophrenia. Alar Pharmaceuticals Inc. was founded in 2016 and is based in Taichung, Taiwan.